Bayer Caught in a Washington Crossfire as Supreme Court Verdict Looms

Bayer's stock wavers as Supreme Court weighs glyphosate liability and Congress removes a key legal shield, with over 100,000 lawsuits pending.

The German pharmaceutical and life sciences giant finds itself squeezed between two Washington power centers this spring, with a Supreme Court ruling that could reshape its legal landscape expected within weeks. The company’s shares have been whipsawed by developments that highlight just how much of Bayer’s future hinges on the US judicial and legislative systems.

A Double Blow from the Capital

On April 30, the House of Representatives voted 280-142 to strip a liability protection clause from the proposed Farm Bill. That clause would have shielded pesticide manufacturers from being held liable for warning labels that go beyond what the Environmental Protection Agency requires. For Bayer, which faces more than 100,000 glyphosate-related lawsuits, the provision would have been a significant legal shield.

The company described the removal to CNBC as “a missed opportunity for Congress.” The bill now moves to the Senate, where similar pressure from both parties is anticipated.

Just days earlier, oral arguments in the case of Monsanto v. Durnell before the Supreme Court offered no clear direction. The core question: Can states hold pesticide makers liable for warning labels that the EPA doesn’t mandate? The justices appeared divided, with some backing the argument for uniform federal labeling standards and others defending states’ rights to act on emerging scientific evidence.

Barclays analyst Charles Pitman-King saw reason for cautious optimism in certain justices’ questioning. JPMorgan’s Richard Vosser noted the high stakes, estimating that the ruling — expected by late June — could influence roughly 80 percent of outstanding glyphosate claims.

The Numbers Behind the Legal Fog

Bayer has already spent more than $11 billion on glyphosate litigation. In February, the company advanced a further $7.25 billion class settlement, which received preliminary approval in March. Claimants have until June 4 to join, and around 61,000 cases remain open, according to the Lawsuit Information Center.

For 2026, Bayer has budgeted roughly €5 billion for legal costs. The company closed last year with a net loss of €3.6 billion as restructuring efforts continue — with measurable results still pending.

The stock currently trades at €37.99, about 23 percent below its 52-week high of €49.17. Still, the shares have gained nearly 58 percent over the past twelve months.

Analyst Optimism Meets Market Reality

Despite the legal overhang, a wave of positive analyst calls has emerged. Deutsche Bank nearly doubled its price target in late April, lifting it from €23 to €43. mwb Research maintains a buy recommendation with a €52 target — implying more than 35 percent upside from current levels. None of the twelve analysts covering Bayer recommend selling.

The company expects adjusted EBITDA for 2026 of between €9.6 billion and €10.1 billion, broadly stable but pressured by generic competition to the blood thinner Xarelto. Management plans to finance legal payouts through credit lines and bond issuances.

What Comes Next

Bayer reports first-quarter results on May 12. The Q1 numbers will offer a fresh look at operational momentum, but the real catalyst remains the Supreme Court decision. If the justices side with Bayer, a large portion of the remaining legal risk could evaporate. A negative ruling would prolong the uncertainty and keep the liability overhang in place.

For now, investors are navigating a stock that offers a 58 percent annual gain but sits well off its highs — a reflection of a company whose fate may be decided not in the lab or the boardroom, but in the marble halls of Washington.